J Yu; T Cooley MD; M-T Truong MD; G Mercier MD, PhD; RM Subramaniam MD, PhD, MPH.
Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters
Article first published online: 3 JUN 2013
© 2013 The Royal Australian and New Zealand College of Radiologists
Journal of Medical Imaging and Radiation Oncology
Volume 58, Issue 1, pages 18–24, February 2014
How to Cite
Yu, J., Cooley, T., Truong, M.-T., Mercier, G. and Subramaniam, R. M. (2014), Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters. Journal of Medical Imaging and Radiation Oncology, 58: 18–24. doi: 10.1111/1754-9485.12081
- Issue published online: 14 FEB 2014
- Article first published online: 3 JUN 2013
- Manuscript Accepted: 30 APR 2013
- Manuscript Received: 4 FEB 2013
- a GE-AUR Research fellowship
- MJ Fox foundation
- MIM Software Inc.
- head and neck;
To evaluate whether the change in the metabolic tumour volume (MTV) or total lesion glycolysis (TLG) of the primary tumour, before and after induction chemotherapy, predicts outcome for patients with advanced head and neck squamous cell cancer (SCC).
Twenty-eight patients with advanced (American Joint Committee on Cancer stage III and IV) head and neck SCC who underwent positron emission tomography (PET)/CT were included in this retrospective study. Primary tumour MTV and TLG were measured using gradient and fixed percentage threshold segmentations. Outcome endpoint was disease progression or mortality. Pearson correlation, Bland–Altman and receiver operator characteristic analysis were performed.
The Pearson's correlation coefficients between percentage changes (pre- and post-induction chemotherapy) from gradient MTV (MTVG) and the 38% SUVmax threshold MTV (MTV38) was 0.96 and between MTVG and the 50% threshold MTV (MTV50) was 0.95 (P < 0.0001). The corresponding Pearson r between TLGG and TLG38 was 0.94 and between TLGG and TLG50 was 0.96 (P < 0.0001). The least bias was 1.89% (standard deviation = 25.30%) between the percentage changes of MTVG and MTV50. The areas under the curve for predicting progression or mortality were 0.76 (P = 0.03) for MTVG and 0.82 for TLGG (P = 0.009). Optimum cut points of a 42% reduction in MTVG and a 55% reduction in the TLGG predict event-free survival with a sensitivity of 62.5% and a specificity of 90% and a hazards ratio of 6.25.
A reduction in primary tumour MTV of at least 42% or in TLG of at least 55% after induction chemotherapy may predict event-free survival in patients with advanced head and neck SCC.